A new study in the UK will investigate the long-term effects of lung inflammation and scarring from COVID-19, Imperial College London announced on Wednesday.
After battling COVID-19, many patients experience long-term symptoms of lung damage, including breathlessness, coughing, fatigue and limited ability to exercise.
The inflammation in the lungs may improve over time, but in some people it persists and in severe cases the lungs may become scarred, Imperial explained.
Supported by GBP2m of funding from UK Research and Innovation (UKRI), the researchers at Imperial aim to develop treatment strategies to prevent the development of severe scarring and disability following COVID-19.
(USD1=GBP0.73)
Precision Epigenomics partners with TruDiagnostic
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Algiax Pharmaceuticals reveals update on chronic neuropathic pain study
SparX Biopharmaceutical doses first subject with SPX-303 injection
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Gabather collaborates with Denmark's Centre for Neuropsychiatric Schizophrenia Research
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms